Amyloid beta peptide is elevated in osteoporotic bone tissues and enhances osteoclast function

Bone

Volumn 61, Issue , 2014, Pages 164-175

  Li, Shangfu ^a   Liu, Bin ^a   Zhang, Liangming ^a   Rong, Limin ^a  

^a THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

Amyloid beta peptide; Amyloid precursor protein; Bone mineral density; Osteoclast; Osteocyte; Osteoporosis

Indexed keywords

AMYLOID BETA PEPTIDE; AMYLOID PRECURSOR PROTEIN; BONE MINERAL DENSITY; OSTEOCLAST; OSTEOCYTE; OSTEOPOROSIS;

AGED; AMYLOID BETA-PEPTIDES; ANIMALS; BLOTTING, WESTERN; BONE DENSITY; CELL DIFFERENTIATION; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MIDDLE AGED; OSTEOCLASTS; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; RATS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SPINAL FRACTURES;

EID: 84893590433     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2014.01.010     Document Type: Article

References (48)

1. Harvey N., Dennison E., Cooper C. Osteoporosis: impact on health and economics. Nat Rev Rheumatol 2010, 6:99-105.
2. Rachner T.D., Khosla S., Hofbauer L.C. Osteoporosis: now and the future. Lancet 2011, 377:1276-1287.
3. Lewiecki E.M. New targets for intervention in the treatment of postmenopausal osteoporosis. Nat Rev Rheumatol 2011, 7:631-638.
4. Nakamura I., Takahashi N., Jimi E., Udagawa N., Suda T. Regulation of osteoclast function. Mod Rheumatol 2012, 22:167-177.
5. Zhang H., Ma Q., Zhang Y.W., Xu H. Proteolytic processing of Alzheimer's beta-amyloid precursor protein. J Neurochem 2012, 120(Suppl. 1):9-21.
6. Goate A.M., Haynes A.R., Owen M.J., Farrall M., James L.A., Lai L.Y., et al. Predisposing locus for Alzheimer's disease on chromosome 21. Lancet 1989, 1:352-355.
7. Harrison R.S., Sharpe P.C., Singh Y., Fairlie D.P. Amyloid peptides and proteins in review. Rev Physiol Biochem Pharmacol 2007, 159:1-77.
8. Koistinen H., Prinjha R., Soden P., Harper A., Banner S.J., Pradat P.F. Elevated levels of amyloid precursor protein in muscle of patients with amyotrophic lateral sclerosis and a mouse model of the disease. Muscle Nerve 2006, 34:444-450.
9. Zhang Y., Zhou B., Zhang F., Wu J., Hu Y., Liu Y., et al. Amyloid-beta induces hepatic insulin resistance by activating JAK2/STAT3/SOCS-1 signaling pathway. Diabetes 2012, 61:1434-1443.
10. Sugarman M.C., Kitazawa M., Baker M., Caiozzo V.J., Querfurth H.W., LaFerla F.M. Pathogenic accumulation of APP in fast twitch muscle of IBM patients and a transgenic model. Neurobiol Aging 2006, 27:423-432.
11. Weller I., Schatzker J. Hip fractures and Alzheimer's disease in elderly institutionalized Canadians. Ann Epidemiol 2004, 14:319-324.
12. Pearson H.A., Peers C. Physiological roles for amyloid beta peptides. J Physiol 2006, 575:5-10.
13. Chasseigneaux S., Allinquant B. Functions of Abeta, sAPPalpha and sAPPbeta: similarities and differences. J Neurochem 2012, 120(Suppl. 1):99-108.
14. Zhao L.N., Long H., Mu Y., Chew L.Y. The toxicity of amyloid beta oligomers. Int J Mol Sci 2012, 13:7303-7327.
15. Cui S., Xiong F., Hong Y., Jung J.U., Li X.S., Liu J.Z., et al. APPswe/Abeta regulation of osteoclast activation and RAGE expression in an age-dependent manner. J Bone Miner Res 2011, 26:1084-1098.
16. Jing D., Shen G., Huang J., Xie K., Cai J., Xu Q., et al. Circadian rhythm affects the preventive role of pulsed electromagnetic fields on ovariectomy-induced osteoporosis in rats. Bone 2010, 46:487-495.
17. Da C.L., Xin Y., Zhao J., Luo X.D. Significance and relationship between Yes-associated protein and survivin expression in gastric carcinoma and precancerous lesions. World J Gastroenterol 2009, 15:4055-4061.
18. Zhu L., Wei H., Wu Y., Yang S., Xiao L., Zhang J., et al. Licorice isoliquiritigenin suppresses RANKL-induced osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo. Int J Biochem Cell Biol 2012, 44:1139-1152.
19. Dahlgren K.N., Manelli A.M., Stine W.B., Baker L.K., Krafft G.A., LaDu M.J. Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J Biol Chem 2002, 277:32046-32053.
20. Francisco J.I., Yu Y., Oliver R.A., Walsh W.R. Relationship between age, skeletal site, and time post-ovariectomy on bone mineral and trabecular microarchitecture in rats. J Orthop Res 2011, 29:189-196.
21. Nakayama T., Mizoguchi T., Uehara S., Yamashita T., Kawahara I., Kobayashi Y., et al. Polarized osteoclasts put marks of tartrate-resistant acid phosphatase on dentin slices-a simple method for identifying polarized osteoclasts. Bone 2011, 49:1331-1339.
22. Salminen A., Ojala J., Kaarniranta K., Kauppinen A. Mitochondrial dysfunction and oxidative stress activate inflammasomes: impact on the aging process and age-related diseases. Cell Mol Life Sci 2012, 69:2999-3013.
23. Melton L.J., Beard C.M., Kokmen E., Atkinson E.J., O'Fallon W.M. Fracture risk in patients with Alzheimer's disease. J Am Geriatr Soc 1994, 42:614-619.
24. Tysiewicz-Dudek M., Pietraszkiewicz F., Drozdzowska B. Alzheimer's disease and osteoporosis: common risk factors or one condition predisposing to the other?. Ortop Traumatol Rehabil 2008, 10:315-323.
25. Roher A.E., Esh C.L., Kokjohn T.A., Castano E.M., Van Vickle G.D., Kalback W.M., et al. Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease. Alzheimers Dement 2009, 5:18-29.
26. Joachim C.L., Mori H., Selkoe D.J. Amyloid beta-protein deposition in tissues other than brain in Alzheimer's disease. Nature 1989, 341:226-230.
27. Chen M., Inestrosa N.C., Ross G.S., Fernandez H.L. Platelets are the primary source of amyloid beta-peptide in human blood. Biochem Biophys Res Commun 1995, 213:96-103.
28. Ghiso J., Calero M., Matsubara E., Governale S., Chuba J., Beavis R., et al. Alzheimer's soluble amyloid beta is a normal component of human urine. FEBS Lett 1997, 408:105-108.
29. Kuo Y.M., Kokjohn T.A., Watson M.D., Woods A.S., Cotter R.J., Sue L.I., et al. Elevated abeta42 in skeletal muscle of Alzheimer disease patients suggests peripheral alterations of AbetaPP metabolism. Am J Pathol 2000, 156:797-805.
30. Schubert W., Prior R., Weidemann A., Dircksen H., Multhaup G., Masters C.L., et al. Localization of Alzheimer beta A4 amyloid precursor protein at central and peripheral synaptic sites. Brain Res 1991, 563:184-194.
31. Rochefort G.Y., Pallu S., Benhamou C.L. Osteocyte: the unrecognized side of bone tissue. Osteoporos Int 2010, 21:1457-1469.
32. McLeod J., Curtis N., Lewis H.D., Good M.A., Fagan M.J., Genever P.G. Gamma-secretase-dependent cleavage of amyloid precursor protein regulates osteoblast behavior. FASEB J 2009, 23:2942-2955.
33. Xia W.F., Jung J.U., Shun C., Xiong S., Xiong L., Shi X.M., et al. Swedish mutant APP suppresses osteoblast differentiation and causes osteoporotic deficit, which are ameliorated by n-acetyl-l-cysteine. J Bone Miner Res 2013, 28(10):2122-2135.
34. Forestier A., Douki T., Sauvaigo S., Rosa V.D., Demeilliers C., Rachidi W. Alzheimer's disease-associated neurotoxic peptide amyloid-beta impairs base excision repair in human neuroblastoma cells. Int J Mol Sci 2012, 13:14766-14787.
35. Clarke B. Normal bone anatomy and physiology. Clin J Am Soc Nephrol 2008, 3(Suppl. 3):S131-S139.
36. Keller A. Breaking and building the wall: the biology of the blood-brain barrier in health and disease. Swiss Med Wkly 2013, 143:w13892.
37. Gosselet F., Saint-Pol J., Candela P., Fenart L. Amyloid-beta peptides, Alzheimer's disease and the blood-brain barrier. Curr Alzheimer Res 2013, 10:1015-1033.
38. Sambrook P., Cooper C. Osteoporosis. Lancet 2006, 367:2010-2018.
39. Goedert M., Spillantini M.G. A century of Alzheimer's disease. Science 2006, 314:777-781.
40. Takayanagi H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol 2007, 7:292-304.
41. Delmas P.D., Eastell R., Garnero P., Seibel M.J., Stepan J., Committee of Scientific Advisors of the International Osteoporosis F The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos Int 2000, 11(Suppl. 6):S2-S17.
42. Naylor K., Eastell R. Bone turnover markers: use in osteoporosis. Nat Rev Rheumatol 2012, 8:379-389.
43. Boyle W.J., Simonet W.S., Lacey D.L. Osteoclast differentiation and activation. Nature 2003, 423:337-342.
44. Rojas A., Delgado-Lopez F., Gonzalez I., Perez-Castro R., Romero J., Rojas I. The receptor for advanced glycation end-products: a complex signaling scenario for a promiscuous receptor. Cell Signal 2013, 25:609-614.
45. Cho H.J., Son S.M., Jin S.M., Hong H.S., Shin D.H., Kim S.J., et al. RAGE regulates BACE1 and Abeta generation via NFAT1 activation in Alzheimer's disease animal model. FASEB J 2009, 23:2639-2649.
46. Zhou Z., Immel D., Xi C.X., Bierhaus A., Feng X., Mei L., et al. Regulation of osteoclast function and bone mass by RAGE. J Exp Med 2006, 203:1067-1080.
47. Kajiya H. Calcium signaling in osteoclast differentiation and bone resorption. Adv Exp Med Biol 2012, 740:917-932.
48. Demuro A., Parker I., Stutzmann G.E. Calcium signaling and amyloid toxicity in Alzheimer disease. J Biol Chem 2010, 285:12463-12468.